PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty REC'D 10 7 NOV 2005

PCT

(PCT Article 36 and Rule 70) WIPO

Applicant's or agent's file reference	FOR FURTHER ACT	ION	See Form PCT/IPEA/416		
DELBE/P32301PC	FUN FUN I HEN ACT				
International application No. PCT/GB2004/005435	International filing date (da 23.12.2004	y/month/year)	Priority date (day/month/year) 23.12.2003		
International Patent Classification (IPC) or national classification and IPC					
C12N15/81, C12N1/19					
Applicant DELTA BIOTECHNOLOGY LIMITE	D et al.				
Authority under Article 35 and trai	nsmitted to the applicant a	according to Afficie 30.	International Preliminary Examining		
2. This REPORT consists of a total of					
3. This report is also accompanied by	by ANNEXES, comprising	:	follower		
a. \square sent to the applicant and t	o the International Bureau	i) a total of sneets, as	nended and are the basis of this report		
and/or sheets containi Administrative Instruc	ing rectifications authorize tions).	d by this Authority (se	e Rule 70.16 and Section 607 of the		
sheets which superse	do carliar chaate but whi	ch this Authority consi- cation as filed, as indic	ders contain an amendment that goes ated in item 4 of Box No. I and the		
Supplemental Box. b. \(\subseteq \text{(sent to the International E} \)	Bureau only) a total of (inc	licate type and numbe	r of electronic carrier(s)) , containing a		
sequence listing and/or tal Box Relating to Sequence	hlee related thereto. In CO	mbliter readable loilli	orly, as indicated in the dupplemental of		
Box Relating to Sequence	Elsting (see Section 602	of the Administrative .	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
4. This report contains indications r	elating to the following ite	ms:			
☐ Box No. I Basis of the op	pinion				
☐ Box No. II Priority					
☐ Box No. III Non-establishr	ment of opinion with regar	d to novelty, inventive	step and industrial applicability		
☐ Box No. IV Lack of unity o	f invention		a de la desentación		
⊠ Box No. V Reasoned state applicability; ci	tement under Article 35(2) Itations and explanations	with regard to novelty supporting such stater	r, inventive step or industrial nent		
☐ Box No. VI Certain docum					
☐ Box No. VII Certain defect					
☐ Box No. VIII Certain observ	ations on the internationa	l application			
Date of submission of the demand		Date of completion of th	is report		
Date of Submitted of the definant					
12.07.2005		07.11.2005			
Name and mailing address of the internation	onal	Authorized Officer			
preliminary examining authority: ———— European Patent Office - P.					
NL-2280 HV Rijswijk - Pays	Bas	Cupido, M	Weight of		
Tel. +31 70 340 - 2040 Tx: Fax: +31 70 340 - 3016	ar par eho III	Telephone No. +31 70	340-3374		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/005435

	Box	x No. I Basis of the r	eport
1.	Wit filed	d, unless otherwise indi	ge, this report is based on the international application in the language in which it was cated under this item.
		which is the language	n translations from the original language into the following language, of a translation furnished for the purposes of: h (under Rules 12.3 and 23.1(b))
		□ publication of the i□ international prelin	nternational application (under Rule 12.4) ninary examination (under Rules 55.2 and/or 55.3)
2.	,	been freezenished to the	nts* of the international application, this report is based on (replacement sheets which e receiving Office in response to an invitation under Article 14 are referred to in this and are not annexed to this report):
	De	escription, Pages	
	69 10	31, 33, 35, 36, 39-41, 44-6 -72, 78-81, 83-89, 91, 93- 1, 102	98,
	32 82	2, 34, 37-38, 42, 43, 66-68 2, 90, 92, 99-100	, 73-77, received on 10.02.2005 with letter of 09.02.2005
	Se	equence listings part of	the description, Pages
		27	received on 10.02.2005 with letter of 09.02.2005
	CI	laims, Numbers	
	1-	63	as originally filed
	Di	rawings, Sheets	
	1/	79-48/79	as originally filed
	49	9/79-79/79	received on 10.02.2005 with letter of 09.02.2005
	×	a sequence listing a	nd/or any related table(s) - see Supplemental Box Relating to Sequence Listing
;	з. ⊏	The amendments h	ave resulted in the cancellation of:
		☐ the description,☐ the claims, Nos.☐ the drawings, sh☐ the sequence lis	neets/figs ting <i>(specify)</i> :
		☐ any table(s) rela	ted to sequence listing <i>(specify)</i> :
	4. E t	☐ This report has been ad not been made, sin Supplemental Box (Rule	en established as if (some of) the amendments annexed to this report and listed below ce they have been considered to go beyond the disclosure as filed, as indicated in the e 70.2(c)).
		☐ the description,	pages
		☐ the claims, Nos☐ the drawings, sl	neets/figs
		The sequence list	sting <i>(specify)</i> : ated to sequence listing <i>(specify)</i> :
		* If item 4 appl	ies, some or all of these sheets may be marked "superseded."

International application No. PCT/GB2004/005435

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No:

1-63

Inventive step (IS)

Yes: Claims

Claims

1-63

No: Claims

Industrial applicability (IA)

Yes: Claims

1-63

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

INTERNATIONAL PRELIMINARY REPORT **ON PATENTABILITY**

International application No. PCT/GB2004/005435

Supplemental Box relating to Sequence Listing

~	ntin	uation	of	Box	I.	item	2:
LJL.	JK I E L A I	ualiuli	vı	$\omega \omega_{\Lambda}$	1.		~~ "

Co	ontinu	ation of Box I, item 2:			
1.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report has been established on the basis of:				
	a. type of material:				
	\boxtimes	a sequence listing			
		table(s) related to the sequence listing			
	b. fo	rmat of material:			
	\boxtimes	l in written format			
	×	in computer readable form			
	c. tin	ne of filing/furnishing:			
		contained in the international application as filed			
		filed together with the international application in computer readable form			
	×	furnished subsequently to this Authority for the purposes of search and/or examination			
	×	received by this Authority as an amendment on			
2.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed as appropriate, were furnished.			
3	. Add	itional observations, if necessary:			

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: WO 00/44772 A (DELTA BIOTECHNOLOGY LIMITED; VAN URK, HENDRIK; MEAD, DAVID, JOHN; MORT) 3 August 2000
- D2: SLEEP DARRELL ET AL: "Yeast 2 mum plasmid copy number is elevated by a mutation in the nuclear gene UBC4" YEAST, vol. 18, no. 5, 30 March 2001, pages 403-421, XP008045518 ISSN: 0749-503X
- D3: US-B1-6 291 205 (TUITE MICHAEL F ET AL) 18 September 2001

By defining a site in the 2μ m-family of plasmid that allows to insert heterologous DNA without creating an unacceptable loss of multicopy stability of the plasmid, the present inventors have overcome the prejudice present in the art for example in D1-D3, that the 2μ m-family plasmids cannot be suitably used as expression vectors. The subject-matter of the present invention is therefore regarded as novel and to involve an inventive step as required by Article 33 PCT.

Re Item VIII

Certain observations on the international application

The invention concerns yeast expression vectors based on the 2μ m-family plasmid, wherein the insertion site for the sequence to be expressed is chosen such that the resulting plasmid is still maintained in a stable manner. However, the subject-matter of claims 48 and 55 and claims dependent thereon concerns **any** yeast vector as long as it has a selectable marker allowing the host cell to survive that cannot be complemented by modifications to the culture medium. However, the essential feature that it has to be a

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/005435

member of the 2μ m-family of plasmids and that the marker gene is inserted in the region specified in claim 1 is missing. This is an essential feature of the invention that has to be mentioned in the claims.